Angiogenesis, Exudation, and Degeneration 2019

February 9, 2019

Bascom Palmer Eye Institute invites you to join us in February 2019 for our sixteenth annual angiogenesis meeting. This unique and exciting symposium entitled Angiogenesis, Exudation, and Degeneration 2019 will be held February 9, 2019 at the Mandarin Oriental Hotel in Miami, Florida. The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
DATE
Saturday, February 9, 2019

LOCATION
Mandarin Oriental Miami
500 Brickell Key Drive
Miami, FL 33131

COURSE CO-DIRECTORS

Philip J. Rosenfeld, MD, PhD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

Harry W. Flynn, Jr., MD
Professor of Ophthalmology
The J. Donald M. Gass Distinguished Chair in Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

Thomas A. Albini, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

COURSE DESCRIPTION

Angiogenesis 2019 follows the tradition of excellence established by Bascom Palmer’s widely acclaimed Angiogenesis programs between 2004 and 2018. Designed for retina specialists, general ophthalmologists and researchers, the current program will review the latest in translational research and clinical trials with an emphasis on how these results will impact clinical ophthalmology. We will emphasize recently completed studies for treatment of a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and retinal degenerations.

COURSE OBJECTIVES

Upon completion of this program, participants should be able to:

- Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases and all the benefits, as well as risks associated with injections of anti-VEGF drugs
- Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
- Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice
- Evaluate the benefits and limitations of combination therapies for exudative macular diseases
- Evaluate the benefits and limitations of different imaging strategies for macular diseases
- Evaluate the emerging imaging technology known as OCT angiography and how this technology might improve clinical management of patients
- Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions and the role of genetics in determining disease progression
7:00 am  Registration and Continental Breakfast
7:50  Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD

SESSION I: Age-Related Macular Degeneration
Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00  Bioenergetics, Metabolism and Macular Degeneration
Philip Luthert, MBBS
8:10  New Data on the Prevalence of AMD
Professor Jean-Francois Korobelnik
8:20  10 Year Follow-up of AREDS2 and More
Emily Y. Chew, MD
8:30  Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Proxima A and B Clinical Trial Results
Nancy M. Holekamp, MD
8:40  Can Genetics Help Identify Individuals with Intermediate AMD at High Risk of Progression?
Johanna M. Seddon, MD, ScM
8:50  Common Age-related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Phase 3 Lampalizumab Trials: Update
Karl G. Csaky, MD, PhD
9:00  Addressing the Cuticular Drusen Epidemic
Lawrence A. Yannuzzi, MD
9:10  Structural/Dynamic/Functional (OCT/OCTA/MP) Assessment of the Macula
Brandon Lujan, MD
9:20  Ultrahigh Speed and Ultrahigh Resolution OCT for Investigating the Outer Retina and Choriocapillaris
James G. Fujimoto, PhD
9:30  Quantitative Assessment of the Choroidal Vasculature Using Swept Source OCTA
Ruikang Wang, PhD
9:40  OCTA of the Choriocapillaris in AMD
Nadia K. Waheed, MD
9:50  SS-OCTA Imaging of Choriocapillaris Flow Deficits in Non-Exudative AMD and Their Correlation with Disease Progression
Philip J. Rosenfeld, MD, PhD

SESSION II: Non-Exudative AMD
Moderators: Thomas A. Albini, MD and Lawrence J. Singerman, MD, FACS
10:00  Retina Trends – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH
10:10  OCT Risk Factors for Development of Late AMD: A Fellow Eye Analysis from the HARBOR Trial
Srinivas Sadda, MD
10:20  Nanosecond Laser Intervention to Slow AMD Progression
Robyn Guymer, MBBS, PhD, FRANZCO
10:30 Soft Drusen Precursors Removed by a Clinical-Stage Apolipoprotein Mimetic Peptide in A Non-human Primate AMD Model
Christine A. Curcio, PhD, FARVO

10:40 Kamuvudines for Macular Degeneration
Jayakrishna Ambati, MD

10:50 Update on Gene Therapy for Complement Inhibition: 1 Year Results of a Phase 1 Study
Jay S. Duker, MD

11:00 Update for the ReCLAIM Trial: Elamipretide for the Treatment of Vision Loss in Drusen and Noncentral GA
Scott W. Cousins, MD

11:10 TOGA – Baseline Characteristics and Preliminary Safety Data
Scott W. Cousins, MD

11:20 Stem Cell Derived RPE Transplantation Surgery for Geographic Atrophy
Amir H. Kashani, MD, PhD

11:30 C3 Inhibition in Geographic Atrophy
Cedric G. Francois, MD, PhD

SESSION III: High Risk Non-Exudative AMD
Moderators: Harry W. Flynn, Jr., MD and Jaclyn L. Kovach, MD

11:40 The Spectrum of Treatment-Naive Subclinical Macular Neovascularization
Giuseppe Querques, MD, PhD

11:50 Two-Year SS-OCTA Incidence and Natural History of Subclinical Neovascularization in Age-Related Macular Degeneration
Philip J. Rosenfeld, MD, PhD

12:00 pm Pearls from PROCON: What Have We Learned in Year 1 of this 2 Year Trial
Jeffrey S. Heier, MD

12:10 Clear Study of Mobile App to Monitor Visual Function in DR and AMD
Lawrence J. Singerman, MD, FACS

12:20 The Future of AMD Management will Include Home OCT Monitoring by Our Patients
Anat Loewenstein, MD, MHA

12:30 Prevention of Exudative CNV in Eyes with High Risk AMD: Theoretical and Practical Challenges in Clinical Trial Design
Daniel F. Martin, MD

12:40 Lunch

SESSION IV: Macular Neovascularization: Imaging and Emerging Therapies
Moderators: Philip J. Rosenfeld, MD, PhD and Ninel Z. Gregori, MD

1:20 Vascular Maturity of Choroidal Neovascularization Evaluated by OCTA
Hiroko Terasaki, MD, PhD

1:30 Polyps in Polypoidal Choroidal Vasculopathy Appear as Tangled Vascular Structures Using Swept-Source OCT Angiography
Fenghua Wang, PhD
1:40 Variations of Choroidal Thickness in CNV
Bruno Lumbroso, MD

1:50 Choroidal Neovascularization: Jekyll or Hyde?
Jason S. Slakter, MD

2:00 Can Exudative AMD Treat Itself?
K. Bailey Freund, MD

2:10 What We Have Learned About Integrins and Their Mechanism of Action
David S. Boyer, MD

2:20 Pan-VEGF Blockade for AMD
Peter K. Kaiser, MD

2:30 KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases
Diana V. Do, MD

2:40 Sustained Release Ranibizumab Therapy: The Phase 2 LADDER Study
Carl D. Regillo, MD, FACS

2:50 Phase 1 Results of GB-102: A Novel Bioabsorbable Sustained-release IVT Depot Formulation of Sunitinib for nAMD (ADAGIO Study)
David S. Boyer, MD

3:00 Subretinal Injection of AAV8 Expressing an Anti-VEGF Protein in Patients with Neovascular AMD
Peter A. Campochiaro, MD

3:10 Gene Therapy for Neovascular AMD: Intravitreal Delivery of AAV-7m8 Vectors
David M. Brown, MD

SESSION V: Macular Neovascularization, Diabetes, and Anti-VEGF Therapy
Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD

3:20 Advances in the Development of an Assisted Intravitreal Injection System
Stephan Michels, MD

3:30 Brolucizumab versus Aflibercept for Neovascular AMD: 96-week Expanded Anatomical Outcomes from HAWK and HARRIER
Pravin U. Dugel, MD

3:40 The Social Cost of Blindness Due to AMD and Diabetes
Andrew A. Moshfeghi, MD, MBA

3:50 Retinal Neurodegeneration and Microangiopathy as Mechanisms of Early DR
Yu Seung-Young, MD

4:00 Relation Between Peripheral and Central Retinal Capillary Non Perfusion is Non Linear in Diabetic Microvascular Disease
Usha Chakravarthy, MD

4:10 Widefield OCT-A in Diabetic Retinopathy
Harry W. Flynn, Jr., MD

4:20 Higher Order Assessment of Optical Coherence Tomography for Quantitative Retinal Features in the VISTA DME Study
Justis P. Ehlers, MD
4:30 Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 1-Year Outcomes of the Phase 3 PANORAMA Study
Charles C. Wykoff, MD

4:40 Comparison of Wide-field OCTA and Ultrawide-field FA Assessment of Capillary Perfusion in Diabetic Retinopathy After Anti-VEGF Therapy
Ramin Tadayoni, MD, PhD

4:50 Preclinical and Emerging Clinical Evidence Supporting the Rationale for Targeting Angiopoietin2 in Diabetic Eye Disease
Peter A. Campochiaro, MD

5:00 Manipulating the Tie2 Pathway in Diabetic Retinopathy
Peter K. Kaiser, MD

SESSION VI: Retinal Vascular Diseases, Uveitis, and Retinal Degenerations
Moderators: Philip J. Rosenfeld, MD, PhD and Janet L. Davis, MD

5:10 Inflammation in Retinal Vascular Diseases: The Role of Interleukin-6 in Age-Related Macular Degeneration and Diabetic Macular Edema
Quan Dong Nguyen, MD

5:20 The Long-Term Physical Stability, Sterility and Anti-VEGF Bio-Activity of Repackaged Bevacizumab in 2 mL Glass Vials: Findings from SCORE2
Michael S. Ip, MD

5:30 Anti-VEGF Therapy in ROP
Darius M. Moshfeghi, MD

5:40 ZIPANGU: A Comparison Study of Anti-VEGF Therapy with or Without OCTA Guided Focal/Grid Laser for Macular Edema Secondary to BRVO
Toshinori Murata, MD, PhD

5:50 Macular Pigment: An Important Technique to Detect Mueller’s Cells Diseases
Giovanni Straurenghi, MD

6:00 Is MacTel a “Serine-Opathy?”
Martin Friedlander, MD, PhD

6:10 A Deep Learning Approach to Quantify Ellipsoid Zone Loss in MacTel2 and Other Macular Diseases
Glenn J. Jaffe, MD

6:20 Suprachoroidal Delivery of Steroids in Uveitis
Thomas A. Albini, MD

6:30 EYS606 - Non Viral Gene Therapy for the Treatment of Non Infectious Uveitis
Sunil K. Srivastava, MD

6:40 Treatments and Clinical Trials in Inherited Retinal Degenerations
Byron L. Lam, MD

6:50 Clinical Trials in Stargardt Disease
Carel B. Hoyng, MD

7:00 Post-Program Test and Closing Remarks

7:05 Adjourn/Cocktail Reception
Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2019

Mandarin Oriental Miami
500 Brickell Key Drive
Miami, FL 33131
Reservations: (800) 526-6566
Direct: (305) 913-8288

Mandarin Oriental Miami is one of America’s finest hotels and recently voted Best Urban Hotel by Miami Herald’s Readers Choice South Florida’s Finest survey-Best of South Florida. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly befits the opulence you’ll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel’s extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

HOTEL RESERVATIONS
For hotel information and reservations, please call 305-913-8288 or 800-526-6566.

The special hotel rate for conference attendees is $429 per night for single or double plus tax. The Mandarin Oriental will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

We suggest you make your hotel reservations as soon as possible as the winter months are the height of South Florida’s tourist season. Bascom Palmer’s preferred room rate will be released after January 9, 2019. Reservations and deposits received after that time are subject to current rates and availability. Please contact the Mandarin Oriental Miami for hotel cancellation policies. For additional information visit: www.mandarinoriental.com/miami

CONFERENCE FEES
Registration rate is $475.
Conference fees include course materials, opening reception, continental breakfast, lunch and refreshment breaks.

CANCELLATION POLICY
Conference tuition, less a $50 cancellation fee, is refundable if notice is received by January 25, 2019. No refunds shall be considered after January 25, 2019 or after sixty (60) days following payment.
TARGET AUDIENCE:
Physicians (retina specialists and general ophthalmologists) and researchers

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

REGISTRATION
Space is limited. Please register early.

To register by internet: Please visit:
http://bascompalmer.org/cme/angiogenesis/registration

To register by mail: Please complete the registration form and return with your check or credit card payment to:
Bascom Palmer Eye Institute
Department of Continuing Medical Education
900 NW 17th Street, Suite 6,
Miami, FL 33136 (Att: Karen Davila)

To register by fax: Please complete the registration form and return with your credit card payment to (305) 326-6518.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 25, 2019.

FOR MORE INFORMATION
Bascom Palmer Eye Institute
Department of Continuing Medical Education at
(305) 326-6110 / Email: bascompalmercme@miami.edu

www.bascompalmer.org

Continuing Medical Education
900 NW 17th Street, Suite 6, Miami, FL 33136
Registration Form

Bascom Palmer Eye Institute

Angiogenesis, Exudation, and Degeneration 2019

February 9, 2019
Registration is limited, so please register early.

Last Name / First Name (as you want it to appear on name badge) / Degree

Last Four Digits of Social Security Number (for record keeping purposes only)

Specialty / Sub-specialty

Affiliated Institution

Address (Check box if new address)

City/State

Country / Zip or Postal Code

Office phone

Office fax

Email

REGISTRATION: $475

Enclosed is my check made payable to Bascom Palmer Eye Institute – Angiogenesis 2019

Please bill my credit card:

[ ] Mastercard

[ ] Visa

[ ] American Express

Card number

[ ]

Security code

Expiration date

Billing zip code

Name on card

Signature

Online: bascompalmer.org/cme/angiogenesis/registration

By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518.

By mail: Please complete this registration form and return with your check or credit card payment to:
Bascom Palmer Eye Institute
Continuing Medical Education Department
900 NW 17th Street, Suite 6
Miami, FL 33136
(Attn: Karen Davila)

By e-mail: bascompalmercme@miami.edu